American Oriental Bioengineering Lands 61 Products On China's Essential Drug List; Innovative R&D Still Best Bet
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - New York-listed American Oriental Bioengineering announced that 61 of its products, including one of its leading products Jinji Yimucao (motherwort), have been included on China's revised national essential drug list
You may also be interested in...
China's Changing Drug Market In The Wake Of Essential Drugs List
SHANGHAI - As an important part of China's $850 billion healthcare reform plan, the Essential Drug List system will bring new challenges as well as opportunities for all players in China's drug supply chain
China's Changing Drug Market In The Wake Of Essential Drugs List
SHANGHAI - As an important part of China's $850 billion healthcare reform plan, the Essential Drug List system will bring new challenges as well as opportunities for all players in China's drug supply chain
Despite Inclusion Of Generics On China's Essential Drug List, Simcere's Leadership Will Keep Focus On Innovative Drugs
BEIJING - While partly attributing an earnings slide, and a dip in sales of its top-selling biopharmaceutical, to the worldwide economic crisis, the leadership of Simcere Pharmaceutical also ruled out the possibility that the inclusion of a wide range of the company's products on China's new Essential Drug List could help trigger a rapid rebound